Drug Type Small molecule drug |
Synonyms DO 2, DO2 |
Target |
Mechanism c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization DeuterOncology SAStartup |
Active Organization DeuterOncology SAStartup |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lung Cancer | Phase 1 | - | DeuterOncology SAStartup | 07 Jun 2023 |
Advanced Malignant Solid Neoplasm | Phase 1 | BE | DeuterOncology SAStartup | 20 Dec 2022 |
Advanced Malignant Solid Neoplasm | Phase 1 | FR | DeuterOncology SAStartup | 20 Dec 2022 |
Advanced Malignant Solid Neoplasm | Phase 1 | NL | DeuterOncology SAStartup | 20 Dec 2022 |
Non-Small Cell Lung Cancer | Phase 1 | BE | DeuterOncology SAStartup | 20 Dec 2022 |
Non-Small Cell Lung Cancer | Phase 1 | FR | DeuterOncology SAStartup | 20 Dec 2022 |
Non-Small Cell Lung Cancer | Phase 1 | NL | DeuterOncology SAStartup | 20 Dec 2022 |
Refractory Malignant Solid Neoplasm | Phase 1 | BE | DeuterOncology SAStartup | 20 Dec 2022 |
Refractory Malignant Solid Neoplasm | Phase 1 | FR | DeuterOncology SAStartup | 20 Dec 2022 |
Refractory Malignant Solid Neoplasm | Phase 1 | NL | DeuterOncology SAStartup | 20 Dec 2022 |